{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-22-002917","form_type":"8-K","ticker":"NAII","cik":"0000787253","company_name":"NATURAL ALTERNATIVES INTERNATIONAL INC","filed_at":"2022-02-10T23:59:59+00:00","discovered_at":"2026-05-14T18:04:09.763744+00:00","generated_at":"2026-06-27T09:23:40.464109+00:00","sec_items":["7.01","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"NAI Q2 FY2022 net sales down 21.5% YoY to $37.7M; diluted EPS $0.30 vs $0.57","bullets":["Net income $1.8M ($0.30 diluted EPS) vs $3.6M ($0.57) in prior-year quarter; private-label sales fell 25.7% to $33.7M.","Sales to largest customer dropped 48%; CarnoSyn beta-alanine revenue up 46.9% to $4.1M; backlog exceeded $12M due to supply chain issues.","FY2022 guidance: net sales flat to slightly up vs FY2021; H2 net sales expected to increase 10%-13% YoY; operating margin 8%-11%.","Cash and equivalents $19.4M; $20.0M available under credit line; new blending capacity online in Vista, CA."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-22-002917","json":"https://secwatch.observer/filing/0001437749-22-002917.json","markdown":"https://secwatch.observer/filing/0001437749-22-002917.md","text":"https://secwatch.observer/filing/0001437749-22-002917.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/787253/000143774922002917/0001437749-22-002917-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/787253/000143774922002917/naii20220209_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-27T09:23:40.464109+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}